Carisma Therapeutics (CARM) News Today $0.86 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Carisma Therapeutics, Inc. (CARM)November 20 at 8:39 AM | finance.yahoo.comCarisma Reports Promising Preclinical Data On Engineered Macrophages For Liver FibrosisNovember 18 at 9:08 AM | markets.businessinsider.comCarisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024November 17, 2024 | prnewswire.comComparing Carisma Therapeutics (NASDAQ:CARM) & Unity Biotechnology (NASDAQ:UBX)November 17, 2024 | americanbankingnews.comOptimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial StandingNovember 12, 2024 | markets.businessinsider.comCarisma Therapeutics Reports Q3 2024 Results, Advances Clinical ProgramsNovember 12, 2024 | msn.comEvercore ISI Remains a Buy on Carisma Therapeutics (CARM)November 10, 2024 | markets.businessinsider.comCarisma Therapeutics reports data from its CAR-M therapyNovember 8, 2024 | markets.businessinsider.comCarisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular CarcinomaNovember 8, 2024 | prnewswire.comCarisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | prnewswire.comCarisma to present new data on CAR-M therapy for hepatocellular carcinomaNovember 5, 2024 | markets.businessinsider.comCarisma Therapeutics Welcomes Sohanya Cheng to Board of DirectorsNovember 5, 2024 | msn.comCarisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024November 5, 2024 | prnewswire.comLeadership Transition at Carisma Therapeutics’ Board of DirectorsNovember 1, 2024 | markets.businessinsider.comEF Hutton Initiates Coverage of Carisma Therapeutics (CARM) with Buy RecommendationNovember 1, 2024 | msn.comCarisma Therapeutics Announces Changes to its Board of DirectorsOctober 30, 2024 | prnewswire.comCarisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024October 8, 2024 | msn.comCarisma Therapeutics Announces Upcoming Presentations at SITC 2024October 4, 2024 | prnewswire.comCarisma, Moderna To Expand Collaboration; Moderna Nominates Two Autoimmune Disease TargetsSeptember 11, 2024 | markets.businessinsider.comCarisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune DiseasesSeptember 10, 2024 | prnewswire.comCarisma Therapeutics CEO to Present at Key Industry ConferencesSeptember 9, 2024 | msn.comCarisma Therapeutics to Present at Upcoming ConferencesSeptember 3, 2024 | prnewswire.comCarisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis TreatmentAugust 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)August 9, 2024 | markets.businessinsider.comCarisma Therapeutics Inc.: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 9, 2024 | finanznachrichten.deCarisma Therapeutics GAAP EPS of -$0.27 beats by $0.03, revenue of $9.2M beats by $5.28MAugust 9, 2024 | msn.comCarisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | prnewswire.comCarisma Therapeutics Announces Expansion of Its Scientific Advisory BoardAugust 6, 2024 | prnewswire.comCarisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024August 6, 2024 | prnewswire.comCan Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?August 3, 2024 | finance.yahoo.comCarisma Therapeutics Announces Changes to its Board of DirectorsJuly 1, 2024 | prnewswire.comCarisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with ModernaJune 27, 2024 | prnewswire.comHC Wainwright Reaffirms "Buy" Rating for Carisma Therapeutics (NASDAQ:CARM)HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of Carisma Therapeutics in a research note on Wednesday.June 26, 2024 | marketbeat.comCarisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid TumorsJune 25, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Stifel 2024 Cell Therapy ForumJune 25, 2024 | prnewswire.comCarisma Therapeutics Announces Adjournment of Annual Meeting of StockholdersJune 13, 2024 | prnewswire.comCarisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest UpdateCarisma Therapeutics, Inc. (NASDAQ:CARM - Get Free Report) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,570,000 shares, a decrease of 13.7% from the April 30th total of 1,820,000 shares. Currently, 7.8% of the company's stock are short sold. Based on an average daily trading volume, of 174,500 shares, the days-to-cover ratio is currently 9.0 days.June 1, 2024 | marketbeat.comCarisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 30, 2024 | prnewswire.comCarisma Therapeutics Launches First Human Trial for CAR-Monocyte TherapyMay 20, 2024 | msn.comBuy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer TherapyMay 17, 2024 | markets.businessinsider.comThe Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 ExpertsMay 17, 2024 | markets.businessinsider.comCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteMay 16, 2024 | prnewswire.comIs There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?May 14, 2024 | finance.yahoo.comCarisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis TreatmentMay 13, 2024 | msn.comBuy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment DevelopmentsMay 10, 2024 | markets.businessinsider.comHC Wainwright Trims Carisma Therapeutics (NASDAQ:CARM) Target Price to $8.00HC Wainwright dropped their price objective on shares of Carisma Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday.May 10, 2024 | marketbeat.comBuy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market GrowthMay 10, 2024 | markets.businessinsider.comCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finanznachrichten.deCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | prnewswire.comCarisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024May 8, 2024 | prnewswire.com Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW CARM Media Mentions By Week CARM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CARM News Sentiment▼0.200.46▲Average Medical News Sentiment CARM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CARM Articles This Week▼41▲CARM Articles Average Week Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cytosorbents News TherapeuticsMD News Sensei Biotherapeutics News Aspira Women's Health News Exagen News Black Diamond Therapeutics News Inventiva News Acumen Pharmaceuticals News Elutia News FitLife Brands News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CARM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts